Prospectus Details Resale of 7 Million Shares by Investor Amidst Delisting Threat

summarizeSummary

Propanc Biopharma filed a prospectus for an investor to resell up to 7 million common shares, representing significant potential dilution, while the company faces a Nasdaq delisting notice and ongoing "going concern" issues.

check_boxKey Events

• Significant Share Resale Registered

  An investor, Hexstone Capital LLC, is registering up to 7,000,000 common shares for resale. This represents approximately 46% of the company's currently outstanding shares, creating a substantial overhang in the market.

• No Direct Proceeds to Company from Resale

  Propanc Biopharma will not receive any direct cash proceeds from the resale of these shares by the selling stockholder.

• Nasdaq Delisting Notice Received

  The company received a Nasdaq delisting notice on December 31, 2025, for failing to maintain a $1.00 minimum bid price, with a compliance deadline of June 30, 2026. The current stock price is significantly below this threshold.

• Ongoing Going Concern Warning

  The company continues to report substantial doubt about its ability to continue as a going concern, citing significant net losses and insufficient cash reserves to meet obligations over the next 12 months.

auto_awesomeAnalysis

This 424B3 filing registers 7 million common shares for resale by Hexstone Capital LLC, an investor who previously provided financing through Series C Preferred Stock and warrants. While the company will not receive direct proceeds from this resale, the sheer volume of shares (approximately 46% of current outstanding shares) creates a substantial overhang and potential for significant dilution for existing shareholders. This event occurs as Propanc Biopharma is under a Nasdaq delisting notice for failing to meet the minimum bid price requirement and continues to report a "going concern" warning due to recurring losses and insufficient cash. The company's precarious financial position makes this large potential share sale particularly impactful, despite recent positive preclinical news.